Strategies for Molecular Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase in Cancer

Journal of Nuclear Medicine

Aviv Hagooly¹  Eyal Mishani¹ 

[1] Cyclotron Unit, Department of Nuclear Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel Cyclotron Unit, Department of Nuclear Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel Cyclotron Unit, Department of Nuclear Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel

关键词: EGFR;    PET;    cancer;    imaging;    tyrosine kinase;    cetuximab;    gefitinib;   

DOI  :  10.2967/jnumed.109.062117

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

A wealth of research has focused on developing targeted cancer therapies by specifically inhibiting epidermal growth factor receptor tyrosine kinase (EGFR-TK). However, the outcome of most EGFR-TK–targeted drugs that were approved by the Food and Drug Administration or entered clinical trials has been only moderate. Enhancement of EGFR-targeted therapy hinges on a reliable in vivo quantitative molecular imaging method. Such a method would enable monitoring of receptor drug binding and receptor occupancy in vivo; determination of the duration of EGFR inhibition in vivo; and, potentially, identification of a primary or secondary mutation in EGFR leading to drug interaction or loss of EGFR recognition by the drug. This review analyzes the most recent strategies to visualize and quantify EGFR-TK in cancer by nuclear medicine imaging and describes future directions.

【 授权许可】

Unknown